NCCN has a significantly active presence in Asia, including an ongoing collaboration with Reno Medical to publish regional adaptations of the NCCN Guidelines® for use in Asia. Adaptations of the NCCN Guidelines are developed by the host country’s oncology thought leaders in conjunction with NCCN Guidelines Panel members. Modified NCCN Guidelines are developed to aid clinicians in determining appropriate and efficient avenues of care in the specified country. Participants include NCCN Guidelines Panel members and a panel of multidisciplinary specialists from China, Japan, South Korea, and Taiwan, who engage in consensus discussions. These adaptations, the Asia Consensus Statements, are English-language manuscripts designed to provide clinical resources for Asian specialists who are involved in the management of cancer patients within the represented countries.
Chinese translations of NCCN Guidelines are available on the International Adaptations & Translations page.
NCCN has also made available a Chinese Website, a valuable online resource for clinical professionals and other health care decision-makers in China.
NCCN has consented to direct non-adapted translations of the Complete Library of NCCN Guidelines into Japanese by a major, national university in Kyoto, Japan. These translations are part of a large endeavor by Foundation for Biomedical Research and Innovation at Kobe to translate the Complete Library of NCCN Guidelines into non-adapted Japanese translations. Each translation of the NCCN Guidelines is managed by the appropriate medical society in Japan to ensure its accuracy for use by Japanese clinicians in the treatment of their patients.
Currently, there are 40 Japanese translations of NCCN Guidelines available. The addition of these translations further strengthens NCCN’s commitment to improving the quality, effectiveness, and efficiency of cancer care regardless of language or geographic barriers.
Korean translations of NCCN Guidelines are available on the International Adaptations & Translations page.